[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-cardiac-arrest-patient-who-was-treated-by-hypothermia-protocol\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-cardiac-arrest-patient-who-was-treated-by-hypothermia-protocol":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100595124",false,"NCT07028372","Long Term Follow-up of Cardiac Arrest Survivors Exposed to Ultra-rapid Cooling","Long Term Follow-up of Cardiac Arrest Survivors Exposed to Ultra-rapid Cooling, a Prospective Non-interventional Cohort","AFTERCOOL","Inclusion Criteria:\n\n* Age of 18 years and over\n* Cardiac arrest patient included in and alive at the end of the OverCool clinical investigation (28 days after the cardiac arrest)\n* Non-opposition from the patient or the trusted person or the close relative or parent obtained within 3 months after the end of the OverCool study\n\nExclusion Criteria:\n\n* Follow-up refusal from patient of trusted person or the close relative or parent\n* Having being included in the OverCool clinical investigation but not submitted to the Vent2Cool procedure\n* Impossibility to reach the patient or the trusted person or the close relative or parent","ALL","18 Years",{"count":19,"type":20},12,"ESTIMATED","OBSERVATIONAL","Less than 10% of patients eliciting out-of-hospital cardiac arrest (OHCA) survive, although 30% can be resuscitated by Emergency services before admission in Intensive Care Units (ICU). The majority succumb to Post-Cardiac Arrest Syndrome (PCAS). PCAS is associated with high mortality (60-70%) and morbidity.\n\nOne proposed method of preventing the neurological and cardiac consequences of PCAS is to lower the body temperature to 33°C as quickly as possible. This approach is known as therapeutic hypothermia or Targeted Temperature Management (TTM). The Vent2Cool system, developed by Orixha, is a novel approach that enables the rapid induction of therapeutic hypothermia by using hypothermic Total Liquid Ventilation (TLV) to reach a protective temperature of 33°C within minutes.\n\nThe OverCool feasibility study, which started in April 2025, is designed to validate the clinical performance and safety of an ultra-rapid cooling approach combining ultra-rapid hypothermia induction using the Vent2Cool system, and maintenance and rewarming using the ArcticSun system.\n\nThe AfterCool study aims to evaluate long-term outcomes during a five-year follow-up of cardiac arrest survivors who were treated with ultrarapid cooling in the OverCool study.",[24,25,26],"Cardiac Arrest (CA)","Resuscitated Sudden Cardiac Death","Post Cardiac Arrest Patient Who Was Treated by Hypothermia Protocol",[28,29,30,31,32,33],"Cardiac arrest","Hypothermia","Target temperature management","Liquid ventilation","Resuscitation","long-term outcomes","RECRUITING","2026-03-22",{"date":37,"type":38},"2026-03-24","ACTUAL",{"date":40,"type":38},"2025-06-11",{"date":42,"type":20},"2031-12",{"name":44,"class":45},"Assistance Publique - Hôpitaux de Paris","OTHER",2,""]